Education
About Us
Working with TipRanks
Follow Us
Harmony Biosciences Holdings, Inc. (HRMY)
:HRMY
HRMY Stock Chart & Stats
$38.78
-$1.07(-3.04%)
At close: 4:00 PM EST
$38.78
-$1.07(-3.04%)
Day’s Range― - ―
52-Week Range$25.52 - $40.93
Previous CloseN/A
Volume87.33K
Average Volume (3M)799.04K
Market Cap
$2.23B
Enterprise Value$1.17B
Total Cash (Recent Filing)$672.58M
Total Debt (Recent Filing)$169.73M
Price to Earnings (P/E)11.8
Beta1.03
Next Earnings
Mar 03, 2026EPS Estimate
0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.87
Shares Outstanding57,596,360
10 Day Avg. Volume810,141
30 Day Avg. Volume799,037
Financial Highlights & Ratios
PEG Ratio0.75
Price to Book (P/B)2.97
Price to Sales (P/S)2.74
P/FCF Ratio8.95
Enterprise Value/Market Cap0.53
Enterprise Value/Revenue1.42
Enterprise Value/Gross Profit1.83
Enterprise Value/Ebitda4.41
Forecast
1Y Price Target
$46.00Price Target Upside18.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessPreliminary open-label extension data from the Phase 3 ARGUS trial showed an approximate 50% reduction in median countable motor seizures for patients with Dravet syndrome, with a favorable safety profile.
Financial PerformanceHarmony ended 3Q25 with $778 million in cash and generated $106 million in quarterly cash flow, underscoring its profitable, self-funding profile.
Revenue GrowthWAKIX delivered 3Q25 net product revenue of $239.5 million, up 29% y/y and 19% sequentially from $200.5 million in 2Q25.
Bears Say
Clinical Trial FailureThe pivotal Phase 3 RECONNECT trial evaluating ZYN002 did not meet the primary endpoint due to a higher-than-anticipated placebo response.
Pipeline ConcernsConcerns exist that the epilepsy program lacks differentiation and the orexin program is entering a crowded market.
Price Target AdjustmentThe price target for Harmony has been lowered to $55 from $70 to reflect the removal of ZYN002 from the model.
Harmony Biosciences Holdings News
HRMY FAQ
What was Harmony Biosciences Holdings, Inc.’s price range in the past 12 months?
Harmony Biosciences Holdings, Inc. lowest stock price was $25.52 and its highest was $40.93 in the past 12 months.
What is Harmony Biosciences Holdings, Inc.’s market cap?
Harmony Biosciences Holdings, Inc.’s market cap is $2.23B.
When is Harmony Biosciences Holdings, Inc.’s upcoming earnings report date?
Harmony Biosciences Holdings, Inc.’s upcoming earnings report date is Mar 03, 2026 which is in 74 days.
How were Harmony Biosciences Holdings, Inc.’s earnings last quarter?
Harmony Biosciences Holdings, Inc. released its earnings results on Nov 04, 2025. The company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.811 by $0.059.
Is Harmony Biosciences Holdings, Inc. overvalued?
According to Wall Street analysts Harmony Biosciences Holdings, Inc.’s price is currently Undervalued.
Does Harmony Biosciences Holdings, Inc. pay dividends?
Harmony Biosciences Holdings, Inc. does not currently pay dividends.
What is Harmony Biosciences Holdings, Inc.’s EPS estimate?
Harmony Biosciences Holdings, Inc.’s EPS estimate is 0.85.
How many shares outstanding does Harmony Biosciences Holdings, Inc. have?
Harmony Biosciences Holdings, Inc. has 57,596,360 shares outstanding.
What happened to Harmony Biosciences Holdings, Inc.’s price movement after its last earnings report?
Harmony Biosciences Holdings, Inc. reported an EPS of $0.87 in its last earnings report, beating expectations of $0.811. Following the earnings report the stock price went up 4.739%.
Which hedge fund is a major shareholder of Harmony Biosciences Holdings, Inc.?
Currently, no hedge funds are holding shares in HRMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Harmony Biosciences Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$46.00 (18.62% Upside)
$46.00 (18.62% Upside)
Blogger Sentiment
Bullish
HRMY Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 147.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.0%
Last 30 Days ▼ 7.6%
Last 30 Days ▼ 7.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.91%
12-Months-Change
Fundamentals
Return on Equity
25.93%
Trailing 12-Months
Asset Growth
30.18%
Trailing 12-Months
Company Description
Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with neurological disorders. The company primarily operates in the healthcare sector, specializing in treatments for conditions such as narcolepsy and other sleep disorders. Harmony's core products include its proprietary medications designed to improve the quality of life for patients suffering from these debilitating conditions.
HRMY Company Deck
HRMY Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong performance in revenue growth and patient adds, showcasing the company's robust cash position and promising pipeline advancements. However, challenges were noted in the Fragile X syndrome study and increased operating expenses.View all HRMY earnings summariesHRMY Stock 12 Month Forecast
Average Price Target
$46.00
▲(18.62% Upside)
Technical Analysis
Ownership Overview
1.04% Insiders
20.56% Mutual Funds
16.12% Other Institutional Investors
34.96% Public Companies and Individual Investors